HBM Healthcare Investments' IFRS loss of CHF78.031 million for fiscal year 2022, compared to a profit of CHF756.271 million in the previous year. The loss from investment activities amounted to CHF75.314 million. Last year the figure was CHF768.78 million.

HBM Healthcare Investments' IFRS net income for 3M 2022 fiscal year was CHF135.988 million, down 39.8% from CHF225.933 million in the previous year. Income from investing activities decreased 39.6% to CHF136.95 million compared to CHF226.88 million a year earlier.

HBM Healthcare Investments is selling a quarter of its 1mg stake to Tata Digital, retaining about 4 percent of the company. 1ms is a leading player in e-health. The company is involved in both telemedicine and drug commerce. Terms of the deal were not disclosed.

HBM Healthcare Investments' IFRS net income for fiscal year 2021 was CHF756.271 million, a four-fold increase from CHF182.698 million in the previous year. Revenue quadrupled to CHF768.78 million compared to CHF188.623 million a year earlier.